Jon Napitupulu

Tonix Pharmaceuticals has outlined a 2026 FDA engagement to shape a Phase 2/3 path for TNX-4800, a long-acting monoclonal...

Transcenta has entered a strategic collaboration and non-exclusive licensing agreement with EirGenix to deploy Transcenta’s Highly Intensified Continuous Bioprocessing...

NTG Nordic Transport Group has appointed Tinneke Torpe as Group CFO, effective no later than April 1, 2026, while...

Genmab has closed a $2.5 billion notes offering—$1.5 billion of 6.250% senior secured notes due 2032 and $1.0 billion...

NKGen Biotech’s majority-owned subsidiary in Seoul has overhauled its governance and identity. NKGen Biotech Korea, formerly NKMAX, completed a...

Nicox has completed the clinical and long-term stability data package required to support New Drug Applications for NCX 470,...

Nicox has completed all clinical and long‑term stability datasets required to support new drug applications for NCX 470, a...

Tempest Therapeutics reported third-quarter 2025 results and moved further into a formal review of strategic alternatives, effectively shifting from...

Senseonics reported third-quarter 2025 revenue of $8.1 million, up 90% year over year, as U.S. new patient starts jumped...

Generation Bio reported third-quarter 2025 results with cash and marketable securities at $89.6 million, down from $185.2 million at...